Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | AHR | P35869 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851915 | 1.00 | LOXL2 (0.58) | LOXL2AHRHRH3HRH4MTNR1A | |
| Methane SCHEMBL29165338 | 0.98 | LOXL2 (0.56) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL30939452 | 0.81 | LOXL2 (0.58) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL396373 | 0.81 | LOXL2 (0.58) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL347687 | 0.81 | LOXL2 (0.58) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL1308753 | 0.81 | LOXL2 (0.58) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL31230610 | 0.78 | LOXL2 (0.55) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL31059889 | 0.77 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL7169246 | 0.77 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4MTNR1A | |
| SCHEMBL401081 | 0.77 | LOXL2 (0.69) | LOXL2AHRHRH3HRH4MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115043846-B | Preparation method of 2-oxo alkyl-9H-pyrrolo [1,2-a ] indol-9-one compound | 西北师范大学 | 2023-09-15 | — | — | CN | claimed |
| CN-115043846-A | Preparation method of 2-oxoalkyl-9H-pyrrolo [1,2-a ] indole-9-ketone compound | 西北师范大学 | 2022-09-13 | — | — | CN | claimed |
| CN-115043846-B | Preparation method of 2-oxo alkyl-9H-pyrrolo [1,2-a ] indol-9-one compound | 西北师范大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-115043846-B | Preparation method of 2-oxo alkyl-9H-pyrrolo [1,2-a ] indol-9-one compound | 西北师范大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-115043846-A | Preparation method of 2-oxoalkyl-9H-pyrrolo [1,2-a ] indole-9-ketone compound | 西北师范大学 | 2022-09-13 | — | — | CN | disclosed |
| CN-115043846-A | Preparation method of 2-oxoalkyl-9H-pyrrolo [1,2-a ] indole-9-ketone compound | 西北师范大学 | 2022-09-13 | — | — | CN | disclosed |
| CN-110698483-B | Synthesis of 2-sulfonyl-9H-pyrrolo [1,2-a ] indole compound | 湖南理工学院 | 2021-12-10 | — | — | CN | disclosed |
| CN-110698483-A | Synthesis of 2-sulfonyl-9H-pyrrolo [1,2-a ] indole compound | 湖南理工学院 | 2020-01-17 | — | — | CN | disclosed |
| CN-109232580-A | A kind of synthetic method of 1H- pyrrolo- [1,2-a] indoles -2 (3-H) -one | 南阳师范学院 | 2019-01-18 | — | — | CN | disclosed |
| CN-100562319-C | 2-cyanopyrrole and pyrimidine and its pharmaceutical use | NOVARTIS AG (CH) | 2009-11-25 | — | — | CN | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| CN-1756553-A | 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-04-05 | — | — | CN | disclosed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | DPYD, P2RY1, P2RY2 | LOXL2 3119/4885AHR 2721/4885HRH3 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.